PURPOSE: This study was designed to test the hypothesis that compression-resistant (CR) scaffolds augmented with recombinant human bone morphogenetic protein-2 (rhBMP-2) at clinically relevant doses in a nonhuman primate lateral ridge augmentation model enhances bone formation in a dose-responsive manner without additional protective membranes. MATERIALS AND METHODS: Defects (15 mm long × 8 mm wide × 5 mm deep) were created bilaterally in the mandibles of nine hamadryas baboons. The defect sites were implanted with poly(ester urethane) (PEUR)/ceramic CR scaffolds augmented with 0 mg/mL rhBMP-2 (CR control), 0.75 mg/mL rhBMP-2 (CR-L), or 1.5 mg/mL rhBMP-2 (CR-H). The primary outcome of ridge width and secondary outcomes of new bone formation, cellular infiltration, and integration with host bone were evaluated using histology, histomorphometry, and microcomputed tomography (micro-CT) at 16 weeks following implantation. RESULTS: New bone formation in the mandible was observed in a dose-responsive manner. CR-H promoted significantly greater new bone formation compared with the CR control group. In all groups, ridge width was maintained without an additional protective membrane. CONCLUSION: CR scaffolds augmented with a clinically relevant dose of rhBMP-2 (1.5 mg/mL) promoted significant new bone formation. These results suggest that a CR PEUR/ceramic composite scaffold without a protective membrane may be a potential new rhBMP-2 carrier for clinical use.
PURPOSE: This study was designed to test the hypothesis that compression-resistant (CR) scaffolds augmented with recombinant humanbone morphogenetic protein-2 (rhBMP-2) at clinically relevant doses in a nonhuman primate lateral ridge augmentation model enhances bone formation in a dose-responsive manner without additional protective membranes. MATERIALS AND METHODS: Defects (15 mm long × 8 mm wide × 5 mm deep) were created bilaterally in the mandibles of nine hamadryas baboons. The defect sites were implanted with poly(ester urethane) (PEUR)/ceramic CR scaffolds augmented with 0 mg/mL rhBMP-2 (CR control), 0.75 mg/mL rhBMP-2 (CR-L), or 1.5 mg/mL rhBMP-2 (CR-H). The primary outcome of ridge width and secondary outcomes of new bone formation, cellular infiltration, and integration with host bone were evaluated using histology, histomorphometry, and microcomputed tomography (micro-CT) at 16 weeks following implantation. RESULTS: New bone formation in the mandible was observed in a dose-responsive manner. CR-H promoted significantly greater new bone formation compared with the CR control group. In all groups, ridge width was maintained without an additional protective membrane. CONCLUSION:CR scaffolds augmented with a clinically relevant dose of rhBMP-2 (1.5 mg/mL) promoted significant new bone formation. These results suggest that a CRPEUR/ceramic composite scaffold without a protective membrane may be a potential new rhBMP-2 carrier for clinical use.
Authors: Ulf M E Wikesjö; Yi-Hao Huang; Andreas V Xiropaidis; Rachel G Sorensen; Michael D Rohrer; Hari S Prasad; John M Wozney; Jan Hall Journal: J Clin Periodontol Date: 2008-11 Impact factor: 8.728
Authors: J M Wozney; V Rosen; A J Celeste; L M Mitsock; M J Whitters; R W Kriz; R M Hewick; E A Wang Journal: Science Date: 1988-12-16 Impact factor: 47.728
Authors: Anne D Talley; Lauren A Boller; Kerem N Kalpakci; Daniel A Shimko; David L Cochran; Scott A Guelcher Journal: Clin Oral Implants Res Date: 2018-05-16 Impact factor: 5.977
Authors: Sichang Lu; Madison A P McGough; Stefanie M Shiels; Katarzyna J Zienkiewicz; Alyssa R Merkel; Joseph P Vanderburgh; Jeffry S Nyman; Julie A Sterling; David J Tennent; Joseph C Wenke; Scott A Guelcher Journal: Biomaterials Date: 2018-06-26 Impact factor: 12.479
Authors: Lauren A Boller; Madison A P McGough; Stefanie M Shiels; Craig L Duvall; Joseph C Wenke; Scott A Guelcher Journal: Materials (Basel) Date: 2021-07-15 Impact factor: 3.623